Kendall Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Kendall Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$612K	Buy	+7,395	New	+$593K	0.1%	152

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kendall Capital Management's ANIP Position: Q2 2026 in Review

Kendall Capital Management opened a new position in ANI Pharmaceuticals (ANIP) in Q2 2026: 7,395 shares worth $612K. The stake represents 0.1% of the portfolio and ranks #152 among its holdings.

307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Kendall Capital Management held 7,395 shares of ANI Pharmaceuticals worth $612K as of Q2 2026.
ANI Pharmaceuticals was a new Kendall Capital Management position in Q2 2026.
ANI Pharmaceuticals made up 0.1% of Kendall Capital Management's portfolio in Q2 2026, its #152 holding.
307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Kendall Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.